NF1 Clinical Trials
Neurofibromatosis type 1 studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect nf1 clinical trial.
Condition
Nf1
Location
Distance
10 miles
50 miles
Any
Age
Search
Clinical Trials
NF1 Clinical Trials
Phase-Based Estimates
1
Effectiveness
1
Safety
OPTIMAL-SSI
for Neurofibromatoses
Richmond, VA
< 18
All Sexes
Recruiting
Richmond, VA
< 18
All Sexes
Children with neurofibromatosis are more likely to have difficulties related to their psychological and neurocognitive functioning (e.g., more likely to have depression, have social difficulties, be diagnosed with ADHD). The purpose of this randomized control study is to determine how effective and useful this study's single session intervention can be in improving psychological and neurocognitive functioning. Enrolled families will consist of one parent/guardian and child. Parents and patients will complete questionnaires and objective tests at baseline, 3 months, and 6 months. Families randomized to the intervention arm will be provided with one single session intervention at Month 1 to learn about their child's testing results and receive psychoeducation and recommendations related to psychological and neurocognitive functioning.
Phase-Based Estimates
1
Effectiveness
1
Safety
ACT Intervention
for Neurofibromatoses
Bethesda, MD
18+
All Sexes
Waitlist Available
Bethesda, MD
18+
All Sexes
Background: RASopathies are a group of genetic diseases that affect a child s development. They cause physical, cognitive, and behavioral symptoms. Caring for a child with a RASopathy can be stressful. Acceptance and Commitment Therapy (ACT) is a therapy that helps people become more aware and accepting of difficult thoughts and feelings. ACT has been found to be helpful for parents with high parenting stress. Objective: To find out if Acceptance and Commitment Therapy (ACT) can help caregivers of children with a RASopathy better cope with parenting stress. Eligibility: People aged 18 years or older who care for a child (younger than 18 years) with a RASopathy. The child must live with the caregiver at least 50% of the time. Design: The study is fully remote. Participants need a mobile device that can play audio and video and connect to the internet. They can borrow an iPod if needed. Participants will download a free app called MetricWire. They will use this app to watch videos and answer questions. The first 8 participants will be in a pilot study. They will receive the ACT intervention starting the first week after they begin the study. After the pilot study, we will start a new phase called the randomized trial. In this phase, participants will have a 50-50 chance of being in the group that will start the intervention right away or the group that will start the intervention after about 2 months. Participants will fill out surveys on 5 random days each week. These surveys have 7 questions and take about 2 minutes. They will also fill out 3 longer questionnaires: once before ACT begins, once just after the 8-week study period, and once about 3 months later. Questions will cover topics including: Parenting stress Life satisfaction Self-compassion Uncomfortable feelings and thoughts Mindfulness Participants will take part in an 8-week ACT intervention. They will have one 75-minute session with an ACT coach in the first week. Participants will watch 9- to 17-minute videos each week. The videos talk about how to practice ACT techniques to cope with parenting stress. Participants will have 20- to 30-minute coaching sessions in weeks 3 and 6. The coach will help them practice exercises and work through any problems.
Phase-Based Estimates
1
Effectiveness
1
Safety
Selumetinib Granule Formulation
for Neurofibromatosis Type 1 (NF1)
Philadelphia, PA
< 18
All Sexes
Phase 1 & 2
Recruiting
Philadelphia, PA
< 18
All Sexes
This study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints. The study will inform the benefit risk profile of the granule formulation in children aged ≥ 1 to < 7 years with NF1 related symptomatic, inoperable PN.
Phase-Based Estimates
1
Effectiveness
1
Safety
Selumetinib
for Neurofibroma
Rochester, MN
< 18
All Sexes
Phase 1
Waitlist Available
Rochester, MN
< 18
All Sexes
This study is evaluating whether a low fat meal can be used to reduce the amount of selumetinib needed to treat NF1.
Phase-Based Estimates
1
Effectiveness
1
Safety
FCN-159
for Watson Syndrome
Detroit, MI
Any Age
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Detroit, MI
Any Age
All Sexes
FCN-159 is a highly active MEK1/2 inhibitor that was designed, synthesized and screened on the basis of the structure of trametinib. FCN-159 is an orally available and highly potent selective inhibitor of MEK1/2, which is expected to be a targeted therapy for the treatment of advanced solid tumors and neurofibromatosis type 1.
Phase-Based Estimates
2
Effectiveness
3
Safety
Selumetinib
for Watson Syndrome
Toronto, Canada
18+
All Sexes
Phase 3
Waitlist Available
Toronto, Canada
18+
All Sexes
This study is evaluating whether selumetinib is effective in treating people with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.
Phase-Based Estimates
1
Effectiveness
1
Safety
PEERS
for Watson Syndrome
Milwaukee, WI
< 18
All Sexes
Recruiting
Milwaukee, WI
< 18
All Sexes
This study is evaluating whether a program which helps teens with neurofibromatosis type 1 make friends may help improve their social skills.
Phase-Based Estimates
1
Effectiveness
1
Safety
Whole-body Magnetic Resonance Imaging
for Watson Syndrome
Los Angeles, CA
< 18
All Sexes
Recruiting
Los Angeles, CA
< 18
All Sexes
This study is evaluating whether a new type of MRI scan may help detect neurofibromatosis type 1.
Phase-Based Estimates
1
Effectiveness
1
Safety
Abemaciclib
for Watson Syndrome
Bethesda, MD
Any Age
All Sexes
Phase 1 & 2
Recruiting
Grade I
Bethesda, MD
Any Age
All Sexes
Background: NF1 is a genetic disease that causes tumors called atypical neurofibromas. These tumors, which arise from nerves, can cause serious medical problems. The only treatment is surgery. Researchers want to see if a drug called abemaciclib can help. Objective: To find a safe, tolerable dose of abemaciclib for treating atypical neurofibromas. Eligibility: People ages 12 and older who have NF1 and have one or more atypical neurofibromas that cannot or will not be removed with surgery Design: Participants will be screened with: Medical history and physical exam Blood, urine, and heart tests MRI: Participants will lie in a machine that takes pictures of the body. A padding or coil will be placed around their head. They may have a contrast agent injected into a vein. Biopsy sample: A small piece of tumor will be removed using a large needle. Participants will have frequent visits during the study. These will include repeats of the screening tests as well as the following: PET scan: Participants will lie in a machine that takes pictures of the body. They will have a contrast agent injected into their arm. Questionnaires about the effects of abemaciclib on pain and quality of life Possible photographs of tumors Participants will take abemaciclib capsules orally twice daily in 28-day cycles. They will take the drug for up to 2 years. Some may be able to take it for longer. Participants will have a follow-up visit about 30 days after their last dose of the study drug. Then they will have visits every 3 months for 1 year.
Phase-Based Estimates
1
Effectiveness
1
Safety
ICanCope
for Watson Syndrome
New Haven, CT
18+
All Sexes
Recruiting
New Haven, CT
18+
All Sexes
This study is evaluating whether a new program may help improve pain and other symptoms for individuals with chronic pain.
Phase-Based Estimates
1
Effectiveness
2
Safety
N-Acetyl Cysteine
for Neurofibroma
Cincinnati, OH
< 18
All Sexes
Phase 2
Recruiting
Locally Advanced
Cincinnati, OH
< 18
All Sexes
This study is evaluating whether N-acetylcysteine may have positive impacts for individuals with neurofibromatosis type 1.
Phase-Based Estimates
1
Effectiveness
2
Safety
Trametinib Dimethyl Sulfoxide
for Multiple Myeloma
Philadelphia, PA
18+
All Sexes
Phase 2
Waitlist Available
Grade IV
Philadelphia, PA
18+
All Sexes
This study is evaluating whether trametinib can shrink a type of cancer that has a genetic change called NF1 mutation.
Phase-Based Estimates
1
Effectiveness
2
Safety
Mirdametinib (PD-0325901) Oral Capsule Or Dispersible Tablet
for Neurofibroma
Louisville, KY
Any Age
All Sexes
Phase 2
Waitlist Available
Louisville, KY
Any Age
All Sexes
This study is evaluating whether a drug may help treat neurofibromatosis type 1.
Phase-Based Estimates
1
Effectiveness
1
Safety
Stress And Symptom Management Program 2
for Neurofibromatoses
Boston, MA
< 18
All Sexes
Recruiting
Boston, MA
< 18
All Sexes
This study is evaluating whether a specific type of therapy may help improve the mental health of adolescents with neurofibromatosis.
Phase-Based Estimates
1
Effectiveness
1
Safety
Whole Body MRI
for Neurofibromatoses
Washington, United States
< 65
All Sexes
Waitlist Available
Washington, United States
< 65
All Sexes
This study is evaluating whether whole body MRI can be used to identify atypical neurofibromas in neurofibromatosis type 1 patients with high tumor burden.
Phase-Based Estimates
1
Effectiveness
1
Safety
Medication Event Monitoring System (MEMS)
for Watson Syndrome
Bethesda, MD
Any Age
All Sexes
Recruiting
Bethesda, MD
Any Age
All Sexes
Background: Neurofibromatosis type 1 (NF1) is a genetic disorder. It has a broad variety of effects on the body. Up to half of people with NF1 get plexiform neurofibromas (PNs). These are benign tumors. But they can have serious effects like pain and disfigurement. To treat PNs, a person may have to take medicine every day for a long period of time. Researchers think that it will be important for people to take the medicine regularly for it to work. They want to study how well people with NF1 follow their treatment plan for PNs. Objective: To study how often people with neurofibromatosis type 1 take medicine that has been prescribed to them for treating plexiform neurofibromas. Eligibility: People ages 3-59 already enrolled in an NF1 clinical trial Design: Participants will need access to the internet to do the study activities. Parents or caregivers will do some study activities for child participants. Participants will complete 5 questionnaires. They will take about 20 minutes total. The topics will be: Demographic data Recent life events How much pain interferes with daily life Ability to focus and pay attention to tasks Emotional distress or depression Participants will mark down every time they take a dose of the medicine in their clinical trial. They will use a form the researchers give them. The pill bottles they get in their trial will have a chip in the cap that will record when it is opened. Participants will keep a daily diary of their medicine. Their pills will be counted at clinical trial visits. Participants may have more short questionnaires. They may have interviews by phone or video.
Phase-Based Estimates
1
Effectiveness
2
Safety
Selumetinib
for Malignant Peripheral Nerve Sheath Tumour (MPNST)
Bethesda, MD
Any Age
All Sexes
Phase 2
Waitlist Available
Metastatic
Bethesda, MD
Any Age
All Sexes
This study is evaluating whether a drug may help treat a type of cancer that is associated with neurofibromatosis type 1.
Phase-Based Estimates
1
Effectiveness
2
Safety
Binimetinib
for Neurofibromatoses
Los Angeles, CA
Any Age
All Sexes
Phase 2
Waitlist Available
Grade III
Los Angeles, CA
Any Age
All Sexes
This study is evaluating whether a drug called binimetinib can shrink tumors in people with neurofibromatosis type 1.
Phase-Based Estimates
1
Effectiveness
2
Safety
Selumetinib Sulfate
for Neurofibroma
Birmingham, AL
18+
All Sexes
Phase 2
Waitlist Available
Grade I
Birmingham, AL
18+
All Sexes
This study is evaluating whether a drug may help treat neurofibromatosis type 1.
Phase-Based Estimates
1
Effectiveness
2
Safety
Selumetinib
for Watson Syndrome
Bethesda, MD
18+
All Sexes
Phase 2
Waitlist Available
Grade I
Bethesda, MD
18+
All Sexes
Background: Neurofibromatosis type 1 (NF1) is a disorder that can cause plexiform neurofibromas (PNs). These are tumors that grow along nerves. Some PNs cause serious health problems. PNs often can t be operated on because of their large size, location, or number. There are no effective treatments known for people with NF1 and PNs. Researchers want to test if the drug selumetinib (AZD6244 hydrogen sulfate) causes PNs to shrink or slows down their growth. Objectives: To test if selumetinib helps treat PNs. To test how the body handles selumetinib and how it affects peoples symptoms. Eligibility: People ages 18 and older with NF1, with an inoperable PN that causes morbidity or is growing Design: Participants will be screened with: Medical history and physical exam Blood, urine, and heart tests Eye exam MRI: They lie in a machine that takes pictures of the body. PN biopsy: A small piece of the tumor is removed by a large needle. Questionnaires Participants will swallow selumetinib capsules every 12 hours for several 28-day cycles. The capsules are taken with a full glass of water on an empty stomach. Participants may have only water for 2 hours before and 1 hour after each dose. Participants will keep a drug diary. They will continue taking the drug as long as they tolerate it and their disease doesn t progress. Participants will have several visits throughout the study. These will include repeats of the screening tests. Participants will have a final visit after they stop taking selumetinib.
Phase-Based Estimates
1
Effectiveness
1
Safety
Turalio
for Watson Syndrome
Bethesda, MD
< 65
All Sexes
Phase 1 & 2
Recruiting
Class III
Bethesda, MD
< 65
All Sexes
Background: - Some people with cancer have solid tumors. Others have refractory leukemia. This doesn t go away after treatment. Researchers want to see if a drug called PLX3397 can shrink tumors or stop them from growing. Objectives: - To find the highest safe dose and side effects of PLX3397. To see if it helps treat certain types of cancer. Eligibility: People ages 3 22 with a solid tumor or leukemia that has returned or not responded to cancer therapies. For Phase II, people ages 3 31 with a Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibroma (PN) that cannot be removed with surgery. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Heart tests Scans or other tests of the tumor Participants will take PLX3397 as a capsule once daily for a 28-day cycle. They can do this for up to 2 years. During the study, participants will have many tests and procedures. They include repeats of the screening tests. Participants will keep a diary of symptoms. Participants with solid tumors will have scans or x-rays. Participants with NF1 PN will have MRI scans. Participants with leukemia will have blood tests. They may have a bone marrow sample taken. Some participants may have a biopsy. When finished taking PLX3397, participants will have follow-up visits. They will repeat the screening tests and note side effects. Phase II will follow the same procedures as Phase I above, but participants will also fill out questionnaires about their pain and quality of life.
Phase-Based Estimates
1
Effectiveness
2
Safety
Cabozantinib
for Neurofibroma, Plexiform
Chicago, IL
Any Age
All Sexes
Phase 2
Waitlist Available
Chicago, IL
Any Age
All Sexes
This study is evaluating whether a drug called cabozantinib might help shrink tumors in people with neurofibromatosis type 1.
Phase-Based Estimates
1
Effectiveness
1
Safety
AZD6244
for Watson Syndrome
Philadelphia, PA
< 65
All Sexes
Phase 1 & 2
Waitlist Available
Grade I
Philadelphia, PA
< 65
All Sexes
This study is evaluating whether a drug called AZD6244 hydrogen sulfate can shrink tumors in children and young adults with plexiform neurofibromas.
Phase-Based Estimates
1
Effectiveness
1
Safety
Selumetinib
for NF1
Indianapolis, IN
18+
All Sexes
Phase 1 & 2
Waitlist Available
Grade I
Indianapolis, IN
18+
All Sexes
A multi-institutional open-label phase 1/2 trial of selumetinib in combination with AZD5153 and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory/relapsed sarcomas. The phase 2 portion will be for patients with refractory/unresectable NF1-associated MPNST.
Phase-Based Estimates
1
Effectiveness
1
Safety
PEERS
for Neurofibroma
Milwaukee, WI
< 18
All Sexes
Waitlist Available
Milwaukee, WI
< 18
All Sexes
This is an open trial of the UCLA PEERS protocol delivered via Telehealth with teens with neurofibromatosis type 1 whose parents report that they have difficulty making and keeping friends.
Phase-Based Estimates
1
Effectiveness
2
Safety
Poly ICLC
for Glioma
New York, NY
< 65
All Sexes
Phase 2
Recruiting
Grade I
New York, NY
< 65
All Sexes
This study is evaluating whether a drug may help treat low-grade gliomas in children with neurofibromatosis type 1.
Other Trials to Consider
Glucagon Nasal Powder [Baqsimi]
for Diabetes, Autoimmune
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase 1
Recruiting
Cincinnati, OH
< 18
All Sexes
Selumetinib
for Neurofibroma
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase 1
Waitlist Available
Rochester, MN
< 18
All Sexes
Stem Cell Educator Therapy
for Diabetes, Autoimmune
Phase-Based Estimates
1
Effectiveness
2
Safety
Phase 2 & 3
Waitlist Available
Class VI
Hackensack, NJ
Any Age
All Sexes
Selumetinib Granule Formulation
for Neurofibromatosis Type 1 (NF1)
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase 1 & 2
Recruiting
Philadelphia, PA
< 18
All Sexes
FCN-159
for Watson Syndrome
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase 1 & 2
Recruiting
Locally Advanced
Detroit, MI
Any Age
All Sexes
Selumetinib
for Watson Syndrome
Phase-Based Estimates
2
Effectiveness
3
Safety
Phase 3
Waitlist Available
Toronto, Canada
18+
All Sexes
Selumetinib Sulfate
for Watson Syndrome
Phase-Based Estimates
2
Effectiveness
3
Safety
Phase 3
Recruiting
Grade I
Phoenix, AZ
< 65
All Sexes
Summerlunch+ At Home Food Skills Program
for Diabetes Mellitus
Phase-Based Estimates
1
Effectiveness
1
Safety
Recruiting
Toronto, Canada
< 18
All Sexes
Community Health Worker
for Young Adults
Phase-Based Estimates
1
Effectiveness
1
Safety
Waitlist Available
Bronx, NY
18 - 65
All Sexes
T:slim X2 Insulin Pump With Control-IQ Technology 1.5
for Diabetes Mellitus
Phase-Based Estimates
1
Effectiveness
1
Safety
Waitlist Available
Idaho Falls, ID
18+
All Sexes
MiniMed 780G System
for Type 1 Diabetes Mellitus
Phase-Based Estimates
1
Effectiveness
1
Safety
Recruiting
Greenville, NC
Any Age
All Sexes
MiniMed 780G System
for Diabetes, Autoimmune
Phase-Based Estimates
1
Effectiveness
1
Safety
Recruiting
Locally Advanced
Roswell, GA
Any Age
All Sexes
Sensor Augmented MDI Therapy Plus Mobile Application
for Diabetes Mellitus
Phase-Based Estimates
1
Effectiveness
1
Safety
Recruiting
Montreal, Canada
18+
All Sexes
Mindfulness Based Stress Reduction
for Diabetes, Autoimmune
Phase-Based Estimates
1
Effectiveness
1
Safety
Recruiting
Class I
Hershey, PA
18+
All Sexes
Popular Categories
Top 10 Type 1 Diabetes Clinical Trials
Type 1 Diabetes Clinical Trials
Top 10 Diabetes Type 2 Clinical Trials
Diabetes Type 2 Clinical Trials 2022
Top 10 Emphysema Clinical Trials
Emphysema Clinical Trials
Top 10 Psoriatic Arthritis Clinical Trials
Psoriatic Arthritis Clinical Trials
Top 10 GERD Clinical Trials
GERD Clinical Trials
Top 10 Neuroendocrine Tumor Clinical Trials
Neuroendocrine Tumor Clinical Trials
Top 10 Rexulti Clinical Trials
Rexulti Clinical Trials
Top 10 Ticagrelor Clinical Trials
Ticagrelor Clinical Trials
Top 10 Chantix Clinical Trials
Chantix Clinical Trials
Top 10 Movantik Clinical Trials
Movantik Clinical Trials
Top 10 Xiidra Clinical Trials
Xiidra Clinical Trials
Top 10 Accutane Clinical Trials
Accutane Clinical Trials
Top 10 Type 2 Diabetes Clinical Trials
Type 2 Diabetes Clinical Trials 2022
Top 10 Diabetes Type 1 Clinical Trials
Diabetes Type 1 Clinical Trials
Top 10 Anoro Ellipta Clinical Trials
Anoro Ellipta Clinical Trials
Relevant Clinical Trials
Eating Disorder Clinical Trials 2022
OA Clinical Trials
Malaria Clinical Trials
Geographic Atrophy Clinical Trials 2022
Orthopedic Clinical Trials 2022
Ebola Clinical Trials
Liposarcoma Clinical Trials 2022
Parkinsons Disease Clinical Trials 2022
Primary Biliary Cirrhosis Clinical Trials
Anosmia Clinical Trials 2022
Psychological Clinical Trials
Social Anxiety Clinical Trials 2022
Polio Clinical Trials
Lichen Planus Clinical Trials 2022
Pre Diabetes Clinical Trials
Snoring Clinical Trials 2022
PAD Clinical Trials
Epidermolysis Bullosa Clinical Trials 2022
Influenza Clinical Trials 2022
Chondrosarcoma Clinical Trials
Top Oncology Trials
Cancer Clinical Trials 2022
Pancreas Cancer Clinical Trials
Prostate Cancer Clinical Trials
Breast Cancer Clinical Trials
Pancreatic Cancer Clinical Trials
Oncology Clinical Trials
Melanoma Clinical Trials 2022
Multiple Myeloma Clinical Trials
Triple Negative Breast Cancer Clinical Trials
Ovarian Cancer Clinical Trials 2022
Lung Cancer Clinical Trials 2022
Colon Cancer Clinical Trials
CLL Clinical Trials 2022
Small Cell Lung Cancer Clinical Trials 2022
Esophageal Cancer Clinical Trials 2022
Mesothelioma Clinical Trials 2022
Leukemia Clinical Trials
AML Clinical Trials
Bladder Cancer Clinical Trials
Cholangiocarcinoma Clinical Trials 2022
Popular Clinical Trials
COVID Clinical Trials 2022
Depression Clinical Trials 2022
ALS Clinical Trials 2022
Coronavirus Clinical Trials 2022
IVF Clinical Trials
Marijuana Clinical Trials 2022
Type 1 Diabetes Clinical Trials
Lupus Clinical Trials 2022
Tinnitus Clinical Trials
PTSD Clinical Trials 2022
Diabetes Clinical Trials 2022
Rheumatoid Arthritis Clinical Trials
Psoriasis Clinical Trials 2022
Multiple Sclerosis Clinical Trials 2022
Obesity Clinical Trials 2022
Psilocybin Clinical Trials
Weight Loss Clinical Trials 2022
Osteoarthritis Clinical Trials
Lyme Disease Clinical Trials
Retinitis Pigmentosa Clinical Trials
Back to top
461 2nd St., San Francisco, CA
hello@withpower.com
(415) 900-4227
About Us
Join The Team!
Conditions
ADHD
ALS
Asthma
Autism
Eczema
IVF
MDS
Osteoarthritis
Psoriasis
Rheumatoid Arthritis
Locations
Colorado
Florida
Indiana
Maine
Massachusetts
Michigan
New York
Ohio
Pennsylvania
Texas
Cancer Related
Chronic Lymphocytic Leukemia
Esophageal
Leukemia
Lymphoma
Melanoma
Multiple Myeloma
Pancreatic Cancer
Prostate Cancer
Small Cell Lung Cancer
Triple Negative Breast Cancer
Treatments
Contrave
Dsuvia
Epidiolex
Ibrutinib
Kybella
Orkambi
Testosterone
Xarelto
Xiidra
Yondelis
Cities
Anaheim, CA
Baltimore, MD
Boston, MA
Chicago, IL
High Point, NC
Houston, TX
Las Vegas, NV
Los Angeles, CA
Miami, FL
San Diego, CA
Terms of Service
Privacy Policy